Business Context and Reporting Period
This Form 8-K was filed by LabStyle Innovations Corp. (not Dariohealth Corp.) on July 23, 2015. The report details the closing of a private placement offering to fund the global penetration and initial U.S. commercial launch of the Company's Dario™ product, a mobile, cloud-based diabetes management solution.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1,500,079.
- Units Sold: 5,000,263 Units at a purchase price of $0.30 per Unit.
- Securities Issued: 5,000,263 shares of Common Stock and Warrants exercisable for an aggregate of 5,000,270 shares of Common Stock.
- Placement Agent Compensation: Aggregate commission of $91,181 plus 850,044 Placement Agent Warrants.
- Use of Proceeds: Funding for product launch and working capital.
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes and Transaction Structure
The primary material change is the entry into a definitive securities purchase agreement and the subsequent issuance of equity. Each Unit sold consists of:
- One share of Common Stock ($0.0001 par value).
- Two Warrants:
- Series A Warrant: Exercisable for 0.5 shares at $0.30/share; expires 12 months post-closing.
- Series B Warrant: Exercisable for 0.5 shares at $0.40/share; expires 36 months post-closing.
Warrants are exercisable for cash or on a cashless basis if a registration statement is unavailable. The Company agreed to file a registration statement for resale within 60 days and use reasonable best efforts to have it declared effective within 75 days (or 150 days if reviewed by the SEC).
Outlook, Risks, and Contingencies
Management intends to use the proceeds to continue funding the global penetration and U.S. commercial launch of the Dario™ product. The filing includes a cautionary note regarding forward-looking statements, warning that actual results may differ materially due to various risks discussed in other SEC filings. The securities issued are exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, and Regulation S for non-U.S. investors.
Investor Verification Checklist
- Verify the correct registrant name is LabStyle Innovations Corp., not Dariohealth Corp.
- Confirm the total dilution impact of the 5,000,263 new shares and 5,000,270 warrant shares.
- Monitor the filing and effectiveness status of the resale registration statement (due within 60-75 days).
- Review the specific terms of the 850,044 Placement Agent Warrants issued as compensation.
- Assess the company's cash runway given the $1.5M gross proceeds against the costs of a U.S. commercial launch.